EPM2A Antikörper (AA 244-331)
-
- Target Alle EPM2A Antikörper anzeigen
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
-
Bindungsspezifität
- AA 244-331
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser EPM2A Antikörper ist unkonjugiert
-
Applikation
- ELISA, Immunohistochemistry (IHC)
- Kreuzreaktivität
- Human
- Aufreinigung
- Antigen Affinity Purified
- Immunogen
- Recombinant Human Laforin protein (244-331AA)
- Isotyp
- IgG
- Top Product
- Discover our top product EPM2A Primärantikörper
-
-
- Applikationshinweise
- Recommended dilution: IHC:1:20-1:200,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
- Andere Bezeichnung
- EPM2A (EPM2A Produkte)
- Synonyme
- TG-B antikoerper, Tg(TcraK,TcrbK)TG-BFlv antikoerper, EPM2 antikoerper, MELF antikoerper, laforin antikoerper, EPM2A, laforin glucan phosphatase antikoerper, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antikoerper, EPM2A antikoerper, Epm2a antikoerper
- Hintergrund
-
Background: Has both dual-specificity protein phosphatase and glucan phosphatase activities. Together with the E3 ubiquitin ligase NHLRC1/malin, appears to be involved in the clearance of toxic polyglucosan and protein aggregates via multiple pathways. Dephosphorylates phosphotyrosine, phosphoserine and phosphothreonine substrates in vitro. Has also been shown to dephosphorylate MAPT. Shows strong phosphatase activity towards complex carbohydrates in vitro, avoiding glycogen hyperphosphorylation which is associated with reduced branching and formation of insoluble aggregates. Forms a complex with NHLRC1/malin and HSP70, which suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Also promotes proteasome-independent protein degradation through the macroautophagy pathway. Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1.
Aliases: Epilepsy progressive myoclonus type 2 Lafora disease (laforin) antibody, Epilepsy progressive myoclonus type 2A Lafora disease (laforin) antibody, EPM2 antibody, Epm2a antibody, Epm2a gene antibody, EPM2A_HUMAN antibody, Lafora PTPase antibody, Laforin antibody, LAFPTPase antibody, LD antibody, LDE antibody, MELF antibody, RP3-466P17.2 antibody
- UniProt
- O95278
- Pathways
- Cellular Glucan Metabolic Process
-